Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib von Wilkins, Bridget S, Radia, Deepti, Woodley, Claire, Farhi, Sarah El, Keohane, Clodagh, Harrison, Claire N

Volltext

The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms von Keohane, Clodagh, McLornan, Donal P, Sanchez, Katy, Connor, Christopher, Radia, Deepti, Harrison, Claire N

Volltext

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells von Keohane, Clodagh, Kordasti, Shahram, Seidl, Thomas, Perez Abellan, Pilar, Thomas, Nicholas S. B., Harrison, Claire N., McLornan, Donal P., Mufti, Ghulam J.

Volltext

High grade non-germinal centre-like diffuse large B-cell lymphoma double expressor presenting as a hydrocoele von Hogan, Donnacha, Hayes, Brian, Keohane, Clodagh, Hennessey, Derek Barrry

Volltext

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis von Rampotas, Alexandros, Wilson, Matthew R., Lomas, Oliver, Denny, Nicholas, Leary, Heather, Ferguson, Graeme, McKay, Pamela, Ebsworth, Tim, Miller, Jonathan, Shah, Nimish, Martinez‐Calle, Nicolas, Bishton, Mark, Everden, Angharad, Tucker, David, El‐Hassad, Ezzat, Hennessy, Brian, Doherty, Dearbhla, Prideaux, Steve, Faryal, Rehman, Hayat, Amjad, Keohane, Clodagh, Marr, Helen, Gibb, Adam, Pocock, Rachael, Lambert, Jonathan, Lacey, Rachel, Elmusharaf, Nagah, Clifford, Ruth, Eyre, Toby A.

Volltext

The diagnosis and management of erythrocytosis von Keohane, Clodagh, McMullin, Mary Frances, Harrison, Claire

Volltext

Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience von Desterro, Joana, McLornan, Donal P., Curto Garcia, Natalia, O'Sullivan, Jennifer, Alimam, Samah, Keohane, Clodagh, Woodley, Claire, Francis, Yvonne, Kordasti, Shahram, Radia, Deepti H., Harrison, Claire N.

Volltext

Combination therapy with ruxolitinib plus 5‐azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast‐phase myeloproliferative neoplasms von Mwirigi, Anne, Galli, Sofia, Keohane, Clodagh, Raj, Kavita, Radia, Deepti H., Harrison, Claire N., McLornan, Donal P.

Volltext

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older von McDonald, Laura, McCarthy, Peter, Khan, Mohammad, Hogan, Patrick, Kelleher, Eileen C., Murphy, Philip, Quinn, John, Desmond, Ronan, McHugh, Johnny, Strickland, Melanie, Cahill, Mary, Maung, Su Wai, Keohane, Clodagh, O'Neill, Desmond, Ryan, Daniel, Mykytiv, Vitaliy, Enright, Helen

Volltext

Ruxolitinib for myelofibrosis von Keohane, Clodagh, Harrison, Claire

Volltext

Myeloproliferative neoplasms von Houstoun, Conal, Keohane, Clodagh

Volltext

Essential thrombocythemia: new advances in an old disease von Keohane, Clodagh, Harrison, Claire

Volltext

JAK Inhibitors Are Not Associated With a Reduction In Novel Markers Of Thrombosis In Myeloproliferative Neoplasms von Keohane, Clodagh, Katiri, Sophia, Connor, Christopher, Sanchez, Katy, Godfrey, Roxanne, Radia, Deepti H, McLornan, Donal, Harrison, Claire N

Volltext

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms von Keohane, Clodagh, Mesa, Ruben, Harrison, Claire

Volltext

JAK Inhibition Reduces CD25 high CD27+ FOXp3+ T Regulatory Cells and Causes a Silencing Of T Effector Cells In Patients With Myeloproliferative Neoplasms Whilst Promoting a TH17 Ph... von Keohane, Clodagh, Kordasti, Shahram Y, Seidl, Thomas, Abellan, Pilar Perez, Thomas, Nicholas Shaun B., Mufti, Ghulam J, Harrison, Claire N, McLornan, Donal

Volltext

The Role of JAK1/2 Inhibitors in the Treatment of Chronic Myeloproliferative Neoplasms von Keohane, Clodagh, Mesa, Ruben, Harrison, Claire

Volltext

Myeloproliferative neoplasms von Harrison, Claire N, Keohane, Clodagh

Volltext

Treatment and management of myelofibrosis in the era of JAK inhibitors von Keohane, Clodagh, Radia, Deepti H, Harrison, Claire N

Volltext

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients von Nangalia, Jyoti, Massie, Charles, Baxter, E Joanna, Nice, Francesca L, Gundem, Gunes, Wedge, David, Avezov, Edward, Li, Juan, Kollmann, Karoline, Kent, David G., Aziz, Athar, Godfrey, Anna L, Hinton, Jonathan, Martincorena, Inigo, Van Loo, Peter, Jones, Amy V, Guglielmelli, Paola, Tarpey, Patrick, Harding, Heather P, Fitzpatrick, John D, Goudie, Calum T, Ortmann, Christina A, Loughran, Stephen J, Raine, Keiran, Jones, David, Butler, Adam, Teague, Jon W, O'Meara, Sarah, McLaren, Stuart, Bianchi, Michele, Silber, Yvonne, Dimitropolou, Danai, Bloxham, David, Mudie, Laura J, Maddison, Mark, Robinson, Ben, Keohane, Clodagh, MacLean, Cathy, Hill, Kate, Orchard, Kim H., Tauro, Sudhir, Du, Ming-Qing, Greaves, Mel, Bowen, David, Huntly, Brian, Harrison, Claire N, Cross, Nicholas C.P., Ron, David, Vannucchi, Alessandro M, Papaemmanuil, Elli, Campbell, Peter J., Green, Anthony R

Volltext

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum] von Keohane, C, Radia, D.H, Harrison, C.N

Volltext